Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
      • Real World Data
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Acacia Pharma

Evaluate

Thumbnail
March 28, 2022

Why some biotechs should never launch a drug

Acacia just became the latest biotech to suffer the curse of seeing one of its drugs approved.

Thumbnail
August 04, 2020

US FDA approval tracker: July

Article image
Vantage logo
April 17, 2020

Covid-19 adds a new danger to drug launches

Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.

Article image
Vantage logo
March 02, 2020

US FDA approval tracker: February 2020

Article image
Vantage logo
February 27, 2020

Twice-rejected Barhemsys finally gets its nod

Article image
Vantage logo
May 03, 2019

Acacia takes a serious blow to its credibility

Article image
Vantage logo
October 08, 2018

Acacia needs quick recovery from US knockback

Article image
Vantage logo
September 27, 2018

Go or no go? Ionis, Sanofi, Regeneron and Roche await big regulatory decisions

October looks to be a big month for label expansions, with Dupixent and Hemlibra both poised to move into big new patient populations. Meanwhile Ionis is awaiting a…

Article image
Vantage logo
April 09, 2018

First-quarter floats hold amid uncertain climate

Biotech IPOs record another strong quarter, setting the pace for a bumper year of new issues.

Vantage logo
August 16, 2016

Interview – Decision time for Acacia as US filing approaches

Vantage logo
August 12, 2016

Snippet roundup: Lilly pill slips, Mek inhibitors reach limit, Myriad buys

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up